Apaxen Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Out of Business

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Out of Business

Apaxen General Information

Description

Developer of anti-inflammatory therapeutics designed to treat diseases that are associated with NLRP3 inflammasome activation. The company specializes in the discovery of treatments for diseases associated with chronic inflammation and fibrosis that inhibit the interaction of macrophage migration inhibitory factor, enabling medical professionals to treat patients with diseases that depend on chronic NLRP3 Inflammasome activation.

Contact Information

Website
www.apaxen.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Rue Auguste Piccard, 48
  • 6041 Gosselies
  • Belgium
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Rue Auguste Piccard, 48
  • 6041 Gosselies
  • Belgium

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Apaxen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business Completed Out of Business
4. Early Stage VC (Series B) Cancelled Pre-Clinical Trials
3. Early Stage VC 18-Jul-2022 Completed Startup
2. Early Stage VC (Series A) 11-Sep-2019 $3.69M $3.69M Completed Startup
1. Accelerator/Incubator Completed Startup
To view Apaxen’s complete valuation and funding history, request access »

Apaxen Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Preference
To view Apaxen’s complete cap table history, request access »

Apaxen Patents

  • 7

    Total Documents Applications and Grants

  • Total Patents Families

  • 5

    Granted

  • Pending

  • Expiring in next 12 mo

Apaxen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023198833-A1 Compound for the inhibition of the nlrp3 inflammasome Inactive 13-Apr-2022
EP-3142665-A1 Mif inhibitors for the acute or chronic treatment of pulmonary hypertension Active 16-May-2014
EP-3142665-B1 Mif inhibitors for the acute or chronic treatment of pulmonary hypertension Active 16-May-2014
US-10071080-B2 Mif inhibitors for the acute or chronic treatment of pulmonary hypertension Inactive 16-May-2014
US-20170079958-A1 Mif inhibitors for the acute or chronic treatment of pulmonary hypertension Active 16-May-2014 A61K31/423
To view Apaxen’s complete patent history, request access »

Apaxen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Apaxen FAQs

  • When was Apaxen founded?

    Apaxen was founded in 2018.

  • Where is Apaxen headquartered?

    Apaxen is headquartered in Gosselies, Belgium.

  • What is the size of Apaxen?

    Apaxen has 4 total employees.

  • What industry is Apaxen in?

    Apaxen’s primary industry is Drug Discovery.

  • Is Apaxen a private or public company?

    Apaxen is a Private company.

  • What is Apaxen’s current revenue?

    The current revenue for Apaxen is .

  • How much funding has Apaxen raised over time?

    Apaxen has raised $4.72M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process